Study Comparing IV Telisotuzumab Vedotin and IV Docetaxel in Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Inclusion Criteria

• Expected to live at least 12 more weeks.
• Have a specific type of non-small cell lung cancer (NSCLC) with high levels of a protein called c-Met, confirmed by a special lab test.
• Provide a tumor sample for testing c-Met levels.
• Have non-squamous cell NSCLC that is advanced or has spread.
• Know the status of a specific gene mutation called EGFR.
• Have changes in genes other than EGFR that can be targeted by treatments.
• Have measurable cancer according to standard criteria.
• Be in good general health with a performance status score of 0 or 1.
• Have received no more than one previous chemotherapy treatment for advanced cancer.
• Have cancer that has progressed after at least one previous treatment for advanced NSCLC.
• Be suitable for docetaxel treatment as determined by the doctor.
• If cancer has spread to the brain, it must be treated and stable, with no symptoms and minimal steroid use.

Exclusion Criteria

• Have new or untreated cancer spread to the brain.
• Have cancer spread to the lining of the brain or spinal cord.
• Have a type of lung cancer called adenosquamous or neuroendocrine, or have sarcomatoid features.
• Have specific EGFR gene mutations.
• Have received previous treatments targeting c-Met or similar drugs.
• Have had docetaxel treatment before.
• Have a history of other cancers unless treated and inactive for at least 2 years.
• Have certain lung conditions like idiopathic pulmonary fibrosis or active pneumonitis.
• Have unresolved side effects from previous cancer treatments, except for hair loss or anemia.
• Have had major surgery within 21 days before starting the study.
• Have any significant medical conditions as specified in the study protocol.